Manufacturer
GlaxoSmithKline Manufacturing S.p.A
Contents
Belimumab
Indication
Reducing disease activity in adult patients w/ active autoantibody +ve SLE receiving standard therapy.
Instruction
Adult 10 mg/kg IV infusion over 1 hr on days 0, 14 & 28 & at 4-wk intervals thereafter. Patient w/ allergies Premed w/ oral antihistamine w/ or w/o antipyretic before infusion.
Drug interaction
No drug interaction studies have been conducted with BENLYSTA.
In clinical trials of patients with SLE, concomitant administration of mycophenolate mofetil, azathioprine, hydroxychloroquine, methotrexate, non-steroidal anti-inflammatory medications, aspirin, and HMG CoA reductase inhibitors had no significant effect on belimumab exposures (see Pharmacology: Pharmacokinetics under Actions).
Malaysia
